CompletedNot Applicable

Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns

Pakistan64 participantsStarted 2019-10-01

Plain-language summary

Introduction: Early detection is important in treating patients with Eczema Herpeticum (EH), which may arise in paediatric burn patients. As soon as a clinical diagnosis is confirmed, antiviral medications should be started to ensure an early resolution of the disease. Several studies have indicated that acyclovir is the best treatment for EH lesions in the majority of individuals. Objective: Compare efficacy of the prophylactic acyclovir and placebo in preventing eczema Herpeticum in paediatric burn patients

Who can participate

Age range1 Month – 13 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

* age 1 month to ≤ 13 years .10 to 60 percent total body surface area (TBSA) burn. * 2nd and 3rd degree burn Exclusion Criteria * Patients having previous history of skin disease. * Patients having any Comorbidity e.g. Psoriasis, asthma, atopic dermatitis and conjunctivitis. * Immunocompromised patients. * Patients on steroids or chemotherapy. * Patients already having eczema Herpeticum and positive baseline Tzanck smear

What they're measuring

Number of participants with positive Tzanck smear

Timeframe: 1 year

Trial details

NCT IDNCT06380647

SponsorKing Edward Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-09-30

View on ClinicalTrials.gov More Herpes Virus Infection trials